Physician profile
Arthur Goldberg
NPI 1023071487
$5,772.63
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,020 · 2020: $1,347 · 2021: $1,330 · 2022: $74.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $794.27 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $422.37 | 2019-2021 | |
| Genzyme Corporation | $375.43 | 2019-2021 | |
| Janssen Biotech, INC. | $345.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $337.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $314.92 | 2019-2022 | |
| Amgen INC. | $301.57 | 2019-2021 | |
| Lilly USA, LLC | $284.03 | 2019-2021 | |
| Puma Biotechnology, INC. | $244.89 | 2019-2021 | |
| Seagen INC. | $234.40 | 2019-2021 | |
| Celgene Corporation | $174.73 | 2019-2020 | |
| Eisai INC. | $158.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.12 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $117.65 | 2019-2020 | |
| Gilead Sciences, INC. | $115.80 | 2019-2022 |
Show all 45 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.